Endocannabinoids and food consumption: comparisons with benzodiazepine and opioid palatability-dependent appetite.
The endocannabinoid system consists of several endogenous lipids, including anandamide and 2-arachidonoyl-glycerol (2-AG), and constitute a retrograde signalling system, which modulates neurotransmitter release and synaptic plasticity. Specific brain-type cannabinoid receptors (CB(1)) are widely distributed in the central nervous system, and are localized presynaptically. Mounting evidence, reviewed here, indicates that cannabinoids can act to increase food consumption, and cannabinoid CB(1) receptor antagonists/inverse agonists reduce food intake and suppress operant responding for food rewards. Hence, endocannabinoids provide the first example of a retrograde signalling system, which is strongly implicated in the control of food intake. Benzodiazepine and opioid palatability-dependent appetite are well-established processes supported by several sources of convergent evidence; they provide pharmacological benchmarks against which to evaluate the endocannabinoids. To date, evidence that endocannabinoids specifically modulate palatability as an affective evaluative process is insufficient and not compelling. Endocannabinoids may have important clinical utility in the treatment of human obesity and forms of eating disorders.
Cooper
Steven J
SJ
Kissileff Laboratory for the Study of Human Ingestive Behaviour, School of Psychology, University of Liverpool, Liverpool L69 7ZA, UK. sjcooper@liverpool.ac.uk.
D000818:Animals; D001069:Appetite Regulation / Q000187:drug effects / Q000502:physiology*; D001569:Benzodiazepines / Q000494:pharmacology*; D063385:Cannabinoid Receptor Modulators / Q000502:physiology*; D004435:Eating / Q000187:drug effects / Q000502:physiology*; D063388:Endocannabinoids; D001068:Feeding and Eating Disorders / Q000188:drug therapy; D006801:Humans; D009294:Narcotics / Q000494:pharmacology*; D009765:Obesity / Q000188:drug therapy; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists / Q000037:antagonists & inhibitors; D015398:Signal Transduction
D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D009294:Narcotics; D043884:Receptor, Cannabinoid, CB1; D001569:Benzodiazepines